2012
Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open‐label extension trial of the interleukin‐12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis
Langley R, Papp K, Gottlieb A, Krueger G, Gordon K, Williams D, Valdes J, Setze C, Strober B. Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open‐label extension trial of the interleukin‐12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. Journal Of The European Academy Of Dermatology And Venereology 2012, 27: 1252-1261. PMID: 23157612, DOI: 10.1111/j.1468-3083.2012.04705.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedCarcinoma, Basal CellCarcinoma, Squamous CellCardiovascular DiseasesClinical Trials as TopicFemaleHumansInterleukin-12Interleukin-23MaleMiddle AgedPrevalencePsoriasisRandomized Controlled Trials as TopicSeverity of Illness IndexSkin Diseases, InfectiousSkin NeoplasmsTreatment OutcomeConceptsOpen-label extension studyMajor adverse cardiovascular eventsPotential safety signalsSevere psoriasisAdverse eventsParent studyClinical trialsSafety signalsSafety resultsAnti-IL-12/23 treatmentInterleukin-12/23 monoclonal antibodyOpen-label extension trialPhase IIAdverse cardiovascular eventsCardiovascular risk factorsBaseline blood pressureBody mass indexRate of infectionCardiovascular eventsFirst doseSafety findingsBlood pressureIL-12/23Mass indexExtension trial
2011
SAPHO syndrome associated with hidradenitis suppurativa successfully treated with infliximab and methotrexate.
De Souza A, Solomon G, Strober B. SAPHO syndrome associated with hidradenitis suppurativa successfully treated with infliximab and methotrexate. Bulletin Of The NYU Hospital For Joint Disease 2011, 69: 185-7. PMID: 22035400.Peer-Reviewed Original ResearchConceptsHidradenitis suppurativaInflammatory musculoskeletal disordersPrevious ineffective treatmentRefractory SAPHO syndromeSafety of infliximabOral antibioticsComplete remissionSAPHO syndromeFirst doseCutaneous featuresContinued treatmentUnknown etiologyCase reportAcne vulgarisMusculoskeletal disordersIneffective treatmentInfliximabSkin abnormalitiesSyndromeYoung adultsSuppurativaJoint stiffnessTreatmentRemissionArthritis